Targeted drugs used in the treatment of nasopharyngeal carcinoma mainly include monoclonal antibody and tyrosine kinase inhibitors. Monoclonal antibody includes cetuximab and so on, and tyrosine kinase inhibitors include gefitinib, afatinib, etc., which should be used under the guidance of physicians. 1. Monoclonal antibody drugs include cetuximab, panitumumab, bevacizumab, nituzumab, etc. Most of these monoclonal antibody-targeted drugs need to be combined with chemotherapy in order to achieve the best therapeutic effect, and if they are used alone, they generally have a lower control rate of nasopharyngeal carcinoma. 2. Tyrosine kinase inhibitors include gefitinib, erlotinib, afatinib, etc. However, these drugs are still in the stage of clinical research for the treatment of nasopharyngeal carcinoma, and they can not replace chemotherapy completely, and chemotherapy is still the main treatment for advanced or recurrent nasopharyngeal carcinoma. For the targeted drugs used in the treatment of nasopharyngeal cancer, patients should go to hospitals and consult doctors with experience in the use of drugs under the guidance and supervision of individualized use of drugs in order to maximize the effect.